Spire Healthcare Group (LON:SPI) Receives a Downgrade
The stock rating of Spire Healthcare Group (LON:SPI) was cut by investment analysts at Investec to a “Sell”. This has been announced in a recent research report revealed to clients on 3 December. Investec now has a GBX 234.00 Estimated Target Price on the shares, which would indicate a possible downside of -24.14%.
From a total of 7 analysts covering Spire Healthcare Group (LON:SPI) stock, 3 rate it a ”Buy”, 0 a “Sell”, and 4 a ”Hold”. This means that 43% of the ratings are positive. The highest target price is GBX 80 while the lowest target price is GBX 27. The mean of all analyst targets is GBX 57.14 with a 14.08% above today’s (GBX 305.2) stock price. Spire Healthcare Group was the topic of 23 analyst reports since July 23, 2015 according to the firm StockzIntelligence Inc. Berenberg maintained shares on November 26 with “Buy” rating. JP Morgan downgraded shares to “Neutral” rating and GBX 310 target share price in a report from a November 12. JP Morgan maintained SPI stock in a recent report from November 23 with “Neutral” rating. Investec maintained the rating on October 6. Investec has a “Hold” rating and a GBX 375 price target on shares. Finally, Morgan Stanley maintained the stock with “Equal Weight” rating in a report issued on a November 12.
Approximately 158,822 shares of stock traded hands. Spire Healthcare Group PLC (LON:SPI) has risen 0.34% since May 6, 2015 and is uptrending. It has outperformed by 0.62% the S&P500.
Spire Healthcare Group plc is a United Kingdom independent hospital group offering a range of integrated surgical, medical and diagnostic services. The company has a market cap of 1.22 billion GBP. The Firm provides in-patient, daycase and out-patient care from approximately 39 hospitals, around 13 clinics and one specialist care center across England, Wales and Scotland. It has 23.57 P/E ratio. The Firm also owns and operates a sports medicine, physiotherapy and rehabilitation brand, Perform; a screening service, Lifescan, as well as national pathology services.